Retatrutide – Technical Brief (For Research-Use-Only)
1. Identity
Retatrutide is an investigational peptide designed as a triple agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This mechanism enhances metabolic regulation, making it a potential candidate for weight management and diabetes treatment.
2. Mechanism of Action
Retatrutide works by:
- GLP-1 activation: Enhances insulin secretion, reduces appetite, and slows gastric emptying.
- GIP activation: Supports insulin sensitivity and metabolic balance.
- Glucagon receptor activation: Increases energy expenditure and fat metabolism.
3. Uses
Retatrutide is primarily being researched for:
- Obesity management: Helps regulate appetite and energy balance.
- Type 2 diabetes: Improves glucose control and insulin sensitivity.
- Metabolic disorders: Potential applications in lipid metabolism and cardiovascular health.
4. Dosage
While clinical trials are ongoing, suggested dosing protocols for research purposes include:
- Week 1–2: 1mg once per week.
- Week 3–4: 2.5mg once per week.
- Week 5+: 5mg once per week (or as tolerated).
- Administered subcutaneously (abdomen or outer thigh) using an insulin syringe.
5. Safety Profile
- Common side effects: Nausea, mild gastrointestinal discomfort, and injection site irritation.
- Precautions: Avoid use in individuals with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
- Long-term effects: Still under investigation, but early data suggests a favourable safety profile.
6. Storage Guidelines
- Before mixing: Store the lyophilized powder in a refrigerator (2–8°C / 36–46°F), protected from light.
- After mixing: Keep refrigerated and use within 30–45 days.
- Room temperature storage: If necessary, can be kept at up to 30°C (86°F) for a maximum of 21 days, but should not be returned to refrigeration afterward.
- Do not freeze: Freezing a reconstituted vial can degrade the peptide’s integrity.
7. Legality in the UK
Retatrutide is not yet approved for use in the UK and is currently undergoing clinical trials. It is unavailable on the NHS, and its future availability remains uncertain due to budget constraints and the presence of other approved weight-loss medications like Mounjaro (tirzepatide) and Wegovy (semaglutide). If approved, it may be prescribed for obesity and type 2 diabetes, pending regulatory approval from the MHRA (Medicines and Healthcare products Regulatory Agency).
